Akèy › Kansè tete negatif triple › New York › Queens
Etid klinik pou Kansè tete negatif triple nan Queens, NY
15 etid pou Kansè tete negatif triple ap chèche patisipan nan sit nan ak bò kote Queens (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1
- START New York Long Island LLC, Lake Success · 9 mi lwen
Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer
Ap rekriteFaz 1
- NYU Langone Hospital - Long Island, Mineola · 11 mi lwen
Study of AVZO-021 in Patients With Advanced Solid Tumors
Ap rekriteFaz 1/2
- Avenzo Therapeutics Recruiting Site, Mineola · 11 mi lwen
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
Ap rekriteFaz 3
- Perlmutter Cancer Center at NYU Langone Hospital - Long Island ( Site 0073), Mineola · 11 mi lwen
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
Ap rekriteFaz 3
- Clinical Research Alliance ( Site 0086), Westbury · 14 mi lwen
A Study of Pembrolizumab and Ablation (Cryoablation or Histotripsy) in People With Breast Cancer
Ap rekriteFaz 1
- Memorial Sloan Kettering Nassau (Limited Protocol Activites), Rockville Centre · 10 mi lwen
A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer
Ap rekriteFaz 2
- Memorial Sloan Kettering Nassau (All Protocol Activities), Uniondale · 13 mi lwen
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
Ap rekriteFaz 3
- Northwell Health, Lake Success · 9 mi lwen
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
Ap rekriteFaz 1
- NYU Langone Health - Long Island, Mineola · 11 mi lwen
A Study of Cyclophosphamide, Methotrexate, Fluorouracil (CMF) for People With Breast Cancer
Ap rekriteFaz 2
- Memorial Sloan Kettering at Nassau (Limited Protocol Activities), Uniondale · 13 mi lwen
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
Ap rekriteFaz 2/3
- Clinical Research Alliance, Westbury · 14 mi lwen
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
Ap rekriteFaz 1
- START New York Long Island, LLC, Lake Success · 9 mi lwen
Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease
Ap rekriteFaz 2
- Memorial Sloan Kettering Nassau, Uniondale · 13 mi lwen
A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer
Ap rekriteFaz 2
- Memorial Sloan Kettering Nassau (All Protocol Activities), Uniondale · 13 mi lwen
A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer
Ap rekriteFaz 2
- Clinical Research Alliance, Westbury · 14 mi lwen
Etid Kansè tete negatif triple nan lòt vil
- Houston, TX42 etid
- New York City, NY31 etid
- Nashville, TN28 etid
- Los Angeles, CA27 etid
- Boston, MA26 etid
- San Antonio, TX23 etid
- St. Louis, MO21 etid
- Arlington, VA20 etid
- Atlanta, GA20 etid
- Dallas, TX18 etid
- Chicago, IL16 etid
- Columbus, OH16 etid
Lòt etid nan Queens
- Kansè nan tete64 etid
- Kansè Poumon ki pa ti selil49 etid
- Kansè kolorektal31 etid
- Kansè Metastatik28 etid
- Kansè ovè28 etid
- Kansè pwostat27 etid
- Kansè (tout kalite)26 etid
- Kansè Endomèt25 etid
- Kansè poumon22 etid
- Leksemi mieloïd egi21 etid
- Myelom Miltip20 etid
- Kansè pankreyas20 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.